Yushin Company (6482) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
21 Jul, 2026Executive summary
Net sales rose 14.5% year-over-year to ¥18,785 million for the nine months ended December 31, 2024, driven by strong custom-ordered equipment sales in Japan and Europe.
Operating profit increased 7.3% year-over-year to ¥1,405 million, while ordinary profit declined 3.2% due to foreign exchange losses.
Profit attributable to owners of parent grew 5.3% year-over-year to ¥969 million.
Financial highlights
Gross profit improved to ¥7,497 million from ¥6,740 million year-over-year.
Basic earnings per share rose to ¥28.50 from ¥27.06 year-over-year.
Comprehensive income decreased 18.9% year-over-year to ¥1,328 million.
Total assets decreased to ¥40,947 million from ¥42,821 million as of March 31, 2024.
Equity ratio improved to 84.6% from 79.6% at the previous fiscal year-end.
Outlook and guidance
Full-year FY2025 guidance maintained: net sales ¥25,500 million (+8.0% YoY), operating profit ¥2,600 million (+6.7% YoY), profit attributable to owners of parent ¥1,800 million (+6.4% YoY), EPS ¥52.89.
No changes to previously announced forecasts.
Latest events from Yushin Company
- Sales and operating profit surged, but ordinary profit fell on forex losses; outlook steady.6482
Q2 202521 Jul 2026 - Sales surged 19.7% year-over-year, but profit margins narrowed on higher costs.6482
Q1 202521 Jul 2026 - Net sales and profit grew in FY2025, but FY2026 guidance signals declines amid global uncertainty.6482
Q4 202521 Jul 2026 - Operating profit rose despite lower sales, with Asia growth offset by Europe weakness.6482
Q1 202621 Jul 2026 - Profits fell sharply on weak medical equipment sales, but dividends and buybacks are maintained.6482
Q2 202621 Jul 2026 - Profits and sales fell sharply in FY2026, but a strong rebound is forecast for FY2027.6482
Q4 202621 Jul 2026 - Profits and sales fell sharply year-over-year, with Europe showing the largest decline.6482
Q3 202621 Jul 2026